Biotechnology
WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers
* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms * WuXi Biologics will receive an upfro...
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
DiscGenics to Present at 41st Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 5, 2023 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it w...
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...
Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
* Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies * Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused ...
OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneurRobert Forrester and venture capitalist Chau Khuong as independent ...
Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that TST003, its first...
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., ...
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthro...
Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023
SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023. Pavel Printsev,...
Call for Application for 2023 Tsinghua Amgen Scholars Program
BEIJING, Jan. 3, 2023 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thro...
Steakholder Foods® Receives Grant of up to $1M for Collaboration with Umami Meats to 3D Bio-Print Structured Cultivated Fish Products
The company's collaborative initiative with its 3D bio-printer is a significant step forward in the company's commercialization strategy for 2023 REHOVOT, Israel, Jan. 3, 2023 /PRNewswire/ -- Steakholder Foods (Nasdaq: STKH), an international deep-tech food company at the forefront of the cultiv...
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC
* PRO1184 first-in human study initiated and first patients dosed * PRO1160 first-in-human study cleared for initiation in the US * Both PRO1184 and PRO1160 are based on a novel, proprietary, and internally developed linker-drug technology platform SUZHOU, China and WOODINVILLE, Wash., Jan. ...
Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
--Focus on renal disease and mRNA platform portfolios-- --Build out commercialization capabilities in preparation for the potential approval and launch of Nefecon and Xerava inChina in 2023-- --Leverage both in-house discovery and strategic business development to establish industry leadership ...
Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference
SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hema...
Bayer Taiwan Company Ltd. and Berocca Honored at the Asia Pacific Enterprise Awards 2022 Taiwan
SINGAPORE, Jan. 3, 2023 /PRNewswire/ -- The Asia Pacific Enterprise Awards (APEA) 2022 Taiwan is pleased to honor 34 outstanding business leaders and enterprises for their commendable dedication toward spearheadingTaiwan's economic recovery and development. Presented by leading regional NGO Enter...
CStone announces the registrational clinical trial of sugemalimab as first-line treatment in patients with esophageal squamous cell carcinoma met primary endpoints and plans to submit a supplemental NDA to NMPA
* Sugemalimab became the first anti-PD-L1 monoclonal antibody that achieved positive results in the study of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma. * Sugemalimab in combination with chemotherapy demonstrated a statistically ...
Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints
HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") was recently informed that onDecember 29, 2022, Viking Therapeutics, Inc. ("Viking"), a pharmaceutical company inthe United States, filed certain complaints against Ascletis, its founder Dr. J...
Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
GAITHERSBURG, Md., Dec. 31, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination (CI...
Week's Top Stories
Most Reposted
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
[Picked up by 331 media titles]
2024-05-23 10:00SINGAPORE'S XSQUARE TECHNOLOGIES SECURES S$10.5M IN SERIES A FUNDING LED BY WAVEMAKER PARTNERS
[Picked up by 326 media titles]
2024-05-23 10:00Unlock the Future of Innovation: Taiwan's Premier Hardware Expo Hits the Global Stage This October
[Picked up by 314 media titles]
2024-05-24 09:41Ultima Markets partnered with Willis Towers Watson (WTW) to offer US$1 million in fund insurance
[Picked up by 303 media titles]
2024-05-24 12:00Elitery Named Google Cloud Managed Services Provider in Indonesia
[Picked up by 302 media titles]
2024-05-22 17:34